Board of Directors

Andy Sandham (Chairman)

Andy Sandham brings over 30 years experience in building biotechnology businesses. He has played a key role in building successful businesses in pharmaceutical discovery and development in Europe and the USA, serving as a founder and executive of Cantab Pharmaceuticals, Hexagen, Signature BioScience and Ionix Pharmaceuticals. He has also served as non-executive chairman of Syntaxin, Novacta Biosystems, non-executive director of Synosia and was a venture partner with Abingworth LLP. Andy is currently also Chairman and CEO of Kymab, non-executive director of NeurAxon and PBL.

Kate Bingham

Kate is a Managing Partner at SVLS with a focus on biotechnology having joined the company in 1991. Kate currently serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. She has been responsible for past investments in Alantos, Auxilium, ESBATech, Hexagen, Kinetix, KuDOS, Leukosite, Mednova, Micromet, PowderMed, RespiVert and current investments including Bicycle, EUSA and Convergence. Prior to joining SVLS, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm. Kate has a first class degree in Biochemistry from Oxford University and graduated from Harvard Business School with an MBA.

Bruce Booth

Bruce Booth is a Partner in the Life Sciences group and joined Atlas Venture in 2005. He focuses on novel biopharmaceutical products, therapeutic platforms and innovative biomedical technologies. Bruce currently serves on the Boards of Atlas portfolio companies Avila, Bicycle, Miragen, Nimbus, OnQity, ProtAffin and Zafgen. He also works or has worked closely with portfolio companies ARCA Biopharma (NASD:ABIO), Archemix, NxStage Medical (NASD:NXTM), Prestwick (acquired by Biovail, Sept 2008), Proprius (acquired by Cypress Biosciences, Feb 2008), and Stromedix.

Previously, Bruce was an investor with Caxton Health Holdings and before that a consultant with McKinsey & Company. As a British Marshall Scholar, Bruce earned a Doctorate in Molecular Immunology from the Oxford University’s Nuffield Department of Medicine and the Weatherall Institute of Molecular Medicine. Bruce has also authored numerous scientific papers and biotech venture capital review articles, including several in Nature Biotechnology and Nature Reviews Drug Discovery

He serves as a Trustee of the New York Academy of Medicine and in several life sciences advisory roles, including UCB Pharma NewMedicines Science Advisory Board, Beth Israel Deaconess Medical Center’s Accelerating Bench to Bedside effort, and LifeTech Boston seed-stage loan program.

Deborah Harland

Deborah joined SR One in 2005 and leads SR One’s investment activities in Europe. In addition to Bicycle, she is currently a member of the Board of Directors of Protaffin AG and Syntaxin Limited, and is an observer on the board of 7TM Pharma. Deborah was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO on SIX Swiss Exchange, 2007) and Pharmakodex Limited (sold to Orexo) and an observer on the Board of Ablynx (IPO, Euronext Brussels 2007). Prior to SR One, Deborah was part of GSK’s Worldwide Business Development team where she evaluated in-licensing opportunities in the CNS and GI therapeutic areas. Deborah holds a BSc. (Hons.) in Pharmacology from the University of Bath, a PhD in Pharmacology from the University of London, and an MBA from Henley Management College.

Anja König

Anja is a Managing Director at the Novartis Venture Fund in the Basel office. She is active in Switzerland and Europe and also manages a $20m fund in Korea. Anja serves on the board of directors for Nabriva, Heptares, Covagen, Diagnoplex, and Bicycle Therapeutics. Before her appointment to the Novartis Venture Fund she held the position of assistant to the Chairman and CEO of Novartis.

Prior to joining Novartis Anja was an Associate Partner at McKinsey and Company in New York City, a global consultancy, where she was a leader in McKinsey’s North American Pharmaceutical Practice and a knowledge expert on pharmaceutical research and drug discovery. Dr. König has experience working in the US, Europe and Emerging Markets. Anja König is a scientist by training and holds a PhD in physics from Cornell University.

Dave Tapolczay

Dave has 21 years experience of R&D management; his past roles include joint worldwide head of chemistry for Zeneca agrochemicals and senior manager of chemical development for Glaxo. He was responsible for the rapid growth of Cambridge Discovery Chemistry and was a key figure in two successful sales of the company initially to Oxford Molecular and then Millennium Pharmaceuticals. Post this last acquisition Dave was VP of Pharmaceutical Sciences with responsibility for over 230 scientists. On leaving Millennium Dave was a founder of Pharmorphix Ltd which was acquired by Sigma Aldrich Fine Chemicals in August 2006. He has also been involved with the start up of 5 companies all of which are still trading and one of which has been AIM listed. He was most recently VP of Technology Development for GSK pharmaceuticals and is currently the Chief Executive Officer of the Medical Research Council Technology Group (MRCT).

Dave has an international reputation in the pharmaceutical chemical development as well as an outstanding academic track record with a considerable number of patents and publications. He was a visiting Professor at Sussex University and has previously held the position of visiting lecturer at Nottingham, Reading and Durham Universities and a member of both the Technical Opportunities Panel and the User Panel of the EPSRC.

John Tite (CEO)

John joined Bicycle Therapeutics as CEO on formation of the company, prior to this he was Vice President and Head of Discovery Biology for the GSK Biopharm CEDD in which capacity he established the current GSK monoclonal antibody programme and was responsible for all biology support for biopharm discovery and development programmes from target to proof of concept

John graduated with a First Class Honours degree in Zoology from University College London before completing a PhD in Immunology at the Middlesex Hospital Medical School. After post-doctoral training at Yale University Medical School, John returned to the United Kingdom to take up the position of research scientist at the Wellcome Foundation working on the development of the first humanised therapeutic antibody–CAMPATH-1H. He has been involved in the discovery and development of therapeutic antibodies and vaccines since that time and played a key role in the establishment of GSK’s Biopharm CEDD. He also led the strategic alliance with PowderJect on DNA vaccines and was the Chairman of the Board for the Edward Jenner Institute for Vaccine Research. John is a frequent contributor to MRC and CR-UK review panels and is currently a member of the MRC-Technology Scientific Advisory Board.

Sir Greg Winter, FRS

Greg is a scientific pioneer of protein engineering, and therapeutic monoclonal antibodies, and an inventor and entrepreneur. He invented techniques to both humanize (1986) and, later, to make fully human antibodies for therapeutic uses. His technology is used in over two-thirds of the antibody products on the market, including the humanized antibodies Campath-1H, Herceptin, Avastin, Synagis and the first human antibody (Humira) to be approved by the US FDA. Greg was a founder and Board Director of Cambridge Antibody Technology (1989); the company pioneered the use of antibody repertoire technologies to make the human antibodies (floated on the LSE in 1997 and acquired by AstraZeneca in 2006). Greg was also a founder and Board Director of Domantis (2000); the company pioneered the use of domain antibodies, which use only the active portion of a full-sized antibody (and acquired by GSK in 2006). Together with Christian Heinis at the EPFL, Lausanne, he is now trying to develop very small protein mimics based on a covalently-bonded hydrophobic core; this is the technology that underpins Bicycle Therapeutics.

Greg has won several international prizes, including the Prix Louis Jeantet de Medecine (Switzerland) in 1989; the King Faisal International Prize for Medicine (Molecular Immunology, Saudi Arabia) in 1995; the Cancer Research Institute William B. Coley Award (USA) in 1999 and the National Biotechnology Ventures Award (USA) in 2004. Greg is Deputy Director of UK Medical Research Council’s Laboratory of Molecular Biology (LMB), Cambridge, and was formerly Joint Head of the LMB Division of Protein and Nucleic Acid Chemistry. Greg is a graduate and Fellow of Trinity College, Cambridge; a Fellow of the Royal Society and of the Academy of Medical Sciences; an honorary Fellow of the Royal College of Physicians, of the Royal Society of Medicine and of the Australian Academy of Technological Science and Engineering; and a Foreign Member of the Royal Swedish Academy of Engineering Sciences. He received his knighthood in 2004.

To read more about the contribution of the Laboratory of Molecular Biology to the development of Therapeutic Antibodies please visit www2.mrc-lmb.cam.ac.uk/antibody